Literature DB >> 15145962

Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?

Shiew-Mei Huang1, Lawrence J Lesko.   

Abstract

Serious drug-drug interactions have contributed to recent U.S. market withdrawals and also recent nonapprovals of a few new molecular entities. Many of these interactions involved the inhibition or induction of metabolizing enzymes and efflux transporters, resulting in altered systemic exposure and adverse drug reactions or loss of efficacy. In addition to drug-drug interactions, drug-dietary supplement and drug-citrus fruit interactions, among others, could also cause adverse drug reactions or loss of efficacy and are important issues to consider in the evaluation of new drug candidates. This commentary reviews (1). the current understanding of the mechanistic basis of these interactions, (2). issues to consider in the interpretation of study results, and (3). recent labeling examples to illustrate the translation of study results to information useful for patients and health care providers.

Entities:  

Mesh:

Year:  2004        PMID: 15145962     DOI: 10.1177/0091270004265367

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  26 in total

1.  Cytochrome P450 inhibition by three licorice species and fourteen licorice constituents.

Authors:  Guannan Li; Charlotte Simmler; Luying Chen; Dejan Nikolic; Shao-Nong Chen; Guido F Pauli; Richard B van Breemen
Journal:  Eur J Pharm Sci       Date:  2017-07-31       Impact factor: 4.384

2.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

3.  Risk assessment of mechanism-based inactivation in drug-drug interactions.

Authors:  Yasushi Fujioka; Kent L Kunze; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2012-06-08       Impact factor: 3.922

4.  Pomegranate juice does not affect the disposition of simvastatin in healthy subjects.

Authors:  Soo-Jin Park; Chang-Woo Yeo; Eon-Jeong Shim; Hyunmi Kim; Kwang-Hyeon Liu; Jae-Gook Shin; Ji-Hong Shon
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-02-27       Impact factor: 2.441

Review 5.  Influence of dietary substances on intestinal drug metabolism and transport.

Authors:  Christina S Won; Nicholas H Oberlies; Mary F Paine
Journal:  Curr Drug Metab       Date:  2010-11       Impact factor: 3.731

Review 6.  Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system.

Authors:  Chi-Yuan Wu; Leslie Z Benet
Journal:  Pharm Res       Date:  2005-01       Impact factor: 4.200

7.  Clinical risk management in Dutch community pharmacies: the case of drug-drug interactions.

Authors:  Henk Buurma; Peter A G M De Smet; Antoine C G Egberts
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

8.  Assessment of the consistency among three drug compendia in listing and ranking of drug-drug interactions.

Authors:  Božana S Nikolić; Maja S Ilić
Journal:  Bosn J Basic Med Sci       Date:  2013-11       Impact factor: 3.363

Review 9.  Interaction of Citrus Juices with Cyclosporine: Systematic Review and Meta-Analysis.

Authors:  Kannan Sridharan; Gowri Sivaramakrishnan
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

10.  Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens.

Authors:  Daniel Moj; Nina Hanke; Hannah Britz; Sebastian Frechen; Tobias Kanacher; Thomas Wendl; Walter Emil Haefeli; Thorsten Lehr
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.